Abstract:Alzheimer's disease (AD) is the most common cause of dementia, accounting for more than 50 million patients worldwide. Current evidence suggests the exact mechanism behind this devastating disease to be of multifactorial origin, which seriously complicates the quest for an effective disease-modifying therapy, as well as impedes the search for strategic preventative measures. Of interest, preclinical studies point to serotonergic alterations, either induced via selective serotonin reuptake inhibitors or serotonin receptor (ant)agonists, in mitigating AD brain neuropathology next to its clinical symptoms, the latter being supported by a handful of human intervention trials. Additionally, a substantial amount of preclinical trials highlight the potential of diet, fecal microbiota transplantations, as well as pre- and probiotics in modulating the brain's serotonergic neurotransmitter system, starting from the gut. Whether such interventions could truly prevent, reverse or slow down AD progression likewise, should be initially tested in preclinical studies with AD mouse models, including sufficient analytical measurements both in gut and brain. Thereafter, its potential therapeutic effect could be confirmed in rigorously randomized controlled trials in humans, preferentially across the Alzheimer's continuum, but especially from the prodromal up to the mild stages, where both high adherence to such therapies, as well as sufficient room for noticeable enhancement are feasible still. In the end, such studies might aid in the development of a comprehensive approach to tackle this complex multifactorial disease, since serotonin and its derivatives across the microbiota-gut-brain axis might serve as possible biomarkers of disease progression, next to forming a valuable target in AD drug development. In this narrative review, the available evidence concerning the orchestrating role of serotonin within the microbiota-gut-brain axis in the development of AD is summarized and discussed, and general considerations for future studies are highlighted.

Relationship Between 5-HT,5-HT Receptors and Alzheimer Disease

Significances of 5-HT receptors in Alzheimer disease and related drug research progress

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Serotonin receptors - a potential target for the treatment of Alzheimer’s disease

Hippocampal 5-HT1A receptor expression changes in prodromal stages of Alzheimer's disease: Beneficial or deleterious?

Amygdala neuronal dyshomeostasis via 5‐HT receptors mediates mood and cognitive defects in Alzheimer's disease

Meta analysis of association between 5-hydroxytryptamine 6 receptor gene polymorphism and pathogenesis of Alzheimer's disease

Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases

The dopaminergic system and Alzheimer's disease

The 5HT2b Receptor in Alzheimer's Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction

Role of Serotonylation and SERT Posttranslational Modifications in Alzheimer's Disease Pathogenesis

Systemic Modulators: Potential Mechanism for the 5-HT System to Mediate Exercise Amelioration in Alzheimer's Disease.

Research Progress on Alzheimer's Disease and Resveratrol

Serotonin 5-HT6 Receptor Antagonists in Alzheimer’s Disease: Therapeutic Rationale and Current Development Status

Metals homeostasis and related proteins in alzheimer's disease

Neurotransmitter Receptors and Cognitive Dysfunction in Alzheimer's Disease and Parkinson's Disease

The intricate role of CCL5/CCR5 axis in Alzheimer disease

[Relationship Between Oral Microbiota and Alzheimer's Disease].

The role of serotonin within the microbiota-gut-brain axis in the development of Alzheimer's disease: A narrative review

Monoamine alterations in Alzheimer's disease and their implications in comorbid neuropsychiatric symptoms

Alterations in dopamine system and in its connectivity with serotonin in a rat model of Alzheimer’s disease